Tucker, GA – According to filings with the U.S. Securities and Exchange Commission, Guide Therapeutics is raising $8,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Thomas Saylor played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Guide Therapeutics

Guide Therapeutics pioneers new gene therapies by developing field-leading drug delivery vehicles. Using a proprietary screening platform that performs thousands of drug delivery experiments directly in vivo, we identify nanoparticles that deliver DNA or RNA to cell types others cannot reach. We then focus on manufacturing, product development, and target selection, in order to develop drugs internally or partner. Guide has developed methods to perform thousands of in vivo drug delivery experiments at once. Each method is tailored to the payload: mRNA delivery is studied using mRNA, and siRNA delivery is studied using siRNA. Our approach, which has led to awards including Top 10 Emerging Technologies in the World by the World Economic Forum, allows us to pursue gene therapies in cells that cannot be targeted otherwise.

To learn more about Guide Therapeutics, visit http://guidetx.com/

Contact:
Thomas Saylor, Chief Executive Officer
509-863-3501
https://www.linkedin.com/in/trsaylor/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved